Literature DB >> 20575042

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.

Zdenek Racil, Filip Razga, Lucie Buresova, Tomas Jurcek, Dana Dvorakova, Daniela Zackova, Shira Timilsina, Petr Cetkovsky, Jiri Mayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20575042      PMCID： PMC7159453          DOI： 10.1002/ajh.21722

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  8 in total

1.  hOCT 1 and resistance to imatinib.

Authors:  Lucy C Crossman; Brian J Druker; Michael W N Deininger; Munir Pirmohamed; Lihui Wang; Richard E Clark
Journal:  Blood       Date:  2005-08-01       Impact factor: 22.113

2.  Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.

Authors:  X Jiang; Y Zhao; C Smith; M Gasparetto; A Turhan; A Eaves; C Eaves
Journal:  Leukemia       Date:  2007-03-01       Impact factor: 11.528

3.  Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.

Authors:  Deborah L White; Verity A Saunders; Phuong Dang; Jane Engler; Amity Venables; Stephanie Zrim; Andrew Zannettino; Kevin Lynch; Paul W Manley; Timothy Hughes
Journal:  Blood       Date:  2007-08-30       Impact factor: 22.113

4.  Active transport of imatinib into and out of cells: implications for drug resistance.

Authors:  Julia Thomas; Lihui Wang; Richard E Clark; Munir Pirmohamed
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

Review 5.  Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Authors:  J Gabert; E Beillard; V H J van der Velden; W Bi; D Grimwade; N Pallisgaard; G Barbany; G Cazzaniga; J M Cayuela; H Cavé; F Pane; J L E Aerts; D De Micheli; X Thirion; V Pradel; M González; S Viehmann; M Malec; G Saglio; J J M van Dongen
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

6.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

Authors:  E Beillard; N Pallisgaard; V H J van der Velden; W Bi; R Dee; E van der Schoot; E Delabesse; E Macintyre; E Gottardi; G Saglio; F Watzinger; T Lion; J J M van Dongen; P Hokland; J Gabert
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

7.  Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.

Authors:  L Wang; A Giannoudis; S Lane; P Williamson; M Pirmohamed; R E Clark
Journal:  Clin Pharmacol Ther       Date:  2007-06-13       Impact factor: 6.875

8.  OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.

Authors:  Deborah L White; Verity A Saunders; Phuong Dang; Jane Engler; Andrew C W Zannettino; Antony C Cambareri; Steven R Quinn; Paul W Manley; Timothy P Hughes
Journal:  Blood       Date:  2006-04-04       Impact factor: 22.113
  8 in total
  4 in total

1.  OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

Authors:  Jane R Engler; Andrew C W Zannettino; Charles G Bailey; John E J Rasko; Timothy P Hughes; Deborah L White
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

Review 2.  Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?

Authors:  V Némethová; F Rázga
Journal:  Leukemia       Date:  2016-10-21       Impact factor: 11.528

3.  Gene expression patterns as predictive biomarkers in hematology-oncology: principal hurdles on the road to the clinic.

Authors:  Filip Rázga; Veronika Némethová
Journal:  Haematologica       Date:  2017-01       Impact factor: 9.941

4.  The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia.

Authors:  Filip Razga; Zdenek Racil; Katerina Machova Polakova; Lucie Buresova; Hana Klamova; Daniela Zackova; Dana Dvorakova; Vaclava Polivkova; Petr Cetkovsky; Jiri Mayer
Journal:  Int J Hematol       Date:  2011-09-08       Impact factor: 2.490
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.